Ignite Creation Date:
2024-05-06 @ 7:03 AM
Last Modification Date:
2024-10-26 @ 11:44 AM
Study NCT ID:
NCT02456948
Status:
COMPLETED
Last Update Posted:
2020-10-19
First Post:
2015-05-27
Brief Title:
Adjunct Minocyline in Treatment-resistant Depression
Sponsor:
Charite University Berlin Germany
Organization:
Charite University Berlin Germany
Study Overview
Official Title:
A Double-blind Placebo-controlled Randomized Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Unipolar Major Depressive Disorder MDD
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Mino-TRD
Brief Summary:
This study examines the antidepressant efficacy of minocycline as an adjunct to an antidepressant standard treatment AD-ST for patients with unipolar major depressive disorder MDD
Detailed Description:
This is a double-blind placebo-controlled randomized multicenter proof-of-principle trial of adjunctive minocycline for patients with unipolar major depressive disorder MDD The study tests the antidepressant efficacy of minocycline as an adjunct to an antidepressant standard treatment AD-ST for patients with unipolar major depressive disorder MDD The respective AD for which non-response has been documented must be on a stable regimen for at least 14 days prior to inclusion AD-ST will then be continued throughout the trial Trial medication is adjunct oral minocycline 200 mgday or placebo Response to treatment will be measured via the Montgomery-Asberg Depression Rating Scale MADRS The total study duration for each patient will be 6 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None